Cancer reports (Hoboken, N.J.) · 2025
Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Channar Aneeta, Naqvi Syed Arsalan Ahmed, Khan Muhammad Ali, Bibi Arifa, Saxena Akshat, Tripathi Nikita, Iftikhar Ahmad, Raina Ammad, Khakwani Kaneez Zahra Rubab, Riaz Irbaz Bin, Husnain Muhammad
Аннотация
BACKGROUND: The treatment landscape for multiple myeloma continues to evolve. Recently, the addition of anti-CD38 monoclonal antibodies (mAbs) to the triplet regimen, comprising a proteasome inhibitor, an immunomodulatory agent, and a steroid, for transplant-eligible newly diagnosed multiple myeloma (TENDMM) has shown promising results.
AIMS: To evaluate the overall efficacy and safety of quadruplet therapy with an anti-CD38 mAb compared to a triplet regimen.
METHODS: A systematic search of Medline, Scopus, and EMBASE databases from inception to July 2024 identified relevant randomized controlled trials (RCTs). Efficacy and safety outcomes were derived using random-effects meta-analysis. Summarized outcomes include hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS), odds ratios (OR) for response rates, measurable residual disease (MRD) negativity rate, and grade 3 or higher adverse events (G ≥ 3 AEs).
RESULTS: Five RCTs involving 2963 patients were included. A statistically significant PFS was observed for quadruplet therapy when compared to the triplet regimen (HR 0.44; 95% Confidence Interval [CI] 0.35-0.56). PFS benefit was consistent for the standard risk (SR) group (HR 0.38; 95% CI 0.27-0.52) and high risk (HiR) group (HR 0.62; 95% CI 0.41-0.92). No statistically significant benefit was observed for OS (HR 0.55; 95% CI 0.28-1.08). A statistically significant benefit was observed for the overall response rate (OR 1.77; 95% CI 1.02-3.06) and MRD negativity rate (OR 2.67; 95% CI 1.79-3.99). No significant differences were observed for G ≥ 3 AE (OR 1.21; 95% CI 0.92-1.58), lymphopenia (OR 1.09; 95% CI 0.62-1.89), and anemia (OR 1.06; 95% CI 0.83-1.37). However, a significantly increased risk was observed for all-grade thrombocytopenia (OR 1.64; 95% CI 1.37-1.97), neutropenia (OR 2.24; 95% CI 1.67-3.02) and infections (OR 1.88; 95% CI 1.07-3.31).
CONCLUSION: Quadruplet therapy demonstrated a favorable efficacy and safety profile, with consistent benefit across subgroups. The findings support its potential as the new standard of care for TENDMM.
AIMS: To evaluate the overall efficacy and safety of quadruplet therapy with an anti-CD38 mAb compared to a triplet regimen.
METHODS: A systematic search of Medline, Scopus, and EMBASE databases from inception to July 2024 identified relevant randomized controlled trials (RCTs). Efficacy and safety outcomes were derived using random-effects meta-analysis. Summarized outcomes include hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS), odds ratios (OR) for response rates, measurable residual disease (MRD) negativity rate, and grade 3 or higher adverse events (G ≥ 3 AEs).
RESULTS: Five RCTs involving 2963 patients were included. A statistically significant PFS was observed for quadruplet therapy when compared to the triplet regimen (HR 0.44; 95% Confidence Interval [CI] 0.35-0.56). PFS benefit was consistent for the standard risk (SR) group (HR 0.38; 95% CI 0.27-0.52) and high risk (HiR) group (HR 0.62; 95% CI 0.41-0.92). No statistically significant benefit was observed for OS (HR 0.55; 95% CI 0.28-1.08). A statistically significant benefit was observed for the overall response rate (OR 1.77; 95% CI 1.02-3.06) and MRD negativity rate (OR 2.67; 95% CI 1.79-3.99). No significant differences were observed for G ≥ 3 AE (OR 1.21; 95% CI 0.92-1.58), lymphopenia (OR 1.09; 95% CI 0.62-1.89), and anemia (OR 1.06; 95% CI 0.83-1.37). However, a significantly increased risk was observed for all-grade thrombocytopenia (OR 1.64; 95% CI 1.37-1.97), neutropenia (OR 2.24; 95% CI 1.67-3.02) and infections (OR 1.88; 95% CI 1.07-3.31).
CONCLUSION: Quadruplet therapy demonstrated a favorable efficacy and safety profile, with consistent benefit across subgroups. The findings support its potential as the new standard of care for TENDMM.